Martinsried-based MorphoSys, the flag ship of the Munich Biotech Cluster, today reported impressive results for the fiscal year 2015. The revenues of EUR 106.2 million are the highest in the 20 years of the company’s history. This dimension has been significantly impacted by a non-recurring effect attributable to the ending of the collaboration with Celgene. Together with its strong cash position of nearly EUR 300 million, MorphoSys has excellent reserves to focus on its proprietary drug development programmes.
CEO Simon Moroney is optimistic and stated: "The progress made in 2015 has contributed to MorphoSys now having a product pipeline that is broader and more mature than ever before. The first therapeutic antibodies are nearing market approval, bringing us closer to a product-based revenue stream that we expect will grow significantly in the years ahead.” For this aim, MorphoSys is confident enough to go back in the reds, even to tens of millions in 2016. The R&D budget for proprietary drug development is expected to increase to EUR 76 to 83 million. The self-confidence of the biggest Bavarian biotech company with 300 employees has a very solid foundation by its unique and broad product pipeline of more than 100 antibody projects.